Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs

Area of Science:

• Oncology
• Pharmacology
• Drug Repurposing

Background:

• Developing new antitumor agents is costly, time-consuming, and lacks clinical experience.
• Existing non-antineoplastic drugs may possess pleiotropic effects with anti-cancer activity.
• Repurposing established medications offers a potential alternative to novel drug development.

Purpose of the Study:

• To review the anticancer properties of metformin and pioglitazone, commonly used for type II diabetes mellitus.
• To discuss their mechanisms of action, pre-clinical and clinical data, and clinical applicability in oncology.
• To highlight the potential of repurposing these drugs for less toxic cancer therapies.

Main Methods:

• Literature review of pre-clinical (in vitro, in vivo) and clinical studies.
• Analysis of the mode of action of metformin and pioglitazone against cancer cells.
• Evaluation of clinical applicability and safety profiles of these drugs in an oncology context.

Main Results:

• Metformin and pioglitazone exhibit multi-level anti-cancer activity and chemosensitizing properties.
• Evidence suggests these drugs can be effective against various cancer types.
• Existing clinical data supports their potential use in cancer treatment regimens.

Conclusions:

• Repurposing metformin and pioglitazone is a viable strategy for developing novel cancer therapies.
• These drugs offer a potentially less toxic alternative to conventional chemotherapy agents.
• Harnessing their anti-cancer functions can accelerate the translation of research findings to clinical practice.